An Analysis of Histamine 2 Receptor Antagonists and a Proposal for Lafutidine
On April 1st, 2020, the Food and Drug Administration (FDA) made national headlines when it published a press release on the removal of Zantac, a popularly prescribed histamine-2 receptor antagonist in the United States. Due to this removal, and the subsequent fallout, it has become necessary to search for alternative H2RA’s. Lafutidine, a marketed drug…